SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX)

SBI Securities Co. Ltd. purchased a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,500 shares of the company’s stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma at the end of the most recent reporting period.

Separately, FNY Investment Advisers LLC purchased a new stake in Immix Biopharma during the fourth quarter worth $63,000. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Stock Performance

IMMX opened at $1.64 on Wednesday. The business’s fifty day moving average is $1.94 and its two-hundred day moving average is $1.88. The company has a market cap of $45.11 million, a price-to-earnings ratio of -1.93 and a beta of 0.26. Immix Biopharma, Inc. has a one year low of $1.26 and a one year high of $3.35.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Immix Biopharma in a research report on Monday, February 10th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.